Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.

Abroad (travel likely)RecruitingPHASE1

Conditions

Systemic Lupus Erythematosus

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking Union Medical College Hospital, Beijing, China
Contact: Study coordinator (Xiaohong Han, PhD) · hanxiaohong@pumch.cn · 8613810659230
Contact: Principal Investigator (XiaoHong Han, PhD)
Peking Union Medical College Hospital, Beijing, China
Contact: Study coordinator (xiaohong Han) · hanxiaohong@pumch.cn · 86+13810659230
The Clinical Pharmacology Research Center of PUMCH, Beijing, China
Contact: Study coordinator (xiaohong Han) · hanxiaohong@pumch.cn · 86+13810659230

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Abroad (travel likely)RecruitingPHASE2

Beverly Hills, United States · La Palma, United States

A Study of E6742 in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Abroad (travel likely)RecruitingPHASE2

Bengbu, China · Beijing, China

A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Systemic Lupus Erythematosus

Abroad (travel likely)RecruitingPHASE3

Phoenix, United States · Los Angeles, United States